Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05282953 | A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) | PHASE1 | COMPLETED | 32 | — | — | Nov 10, 2022 | Mar 24, 2026 | May 4, 2026 | 3 | Australia |
Number of participants with treatment-related adverse events as assessed by overall changes in retinal thickness and appearance, clinical chemistry and hematology, and other eye assessments.
| Arm | Type | Description |
|---|---|---|
| Patients with Retinitis Pigmentosa and Choroideremia | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| KIO-301 | DRUG | KIO-301 intravitreal injection at ascending doses |
Main Study: Inclusion Criteria 1. Be aged 18 to 80 years at Visit 1 of either sex and of any race. 2. Be willing and able to provide informed consent either written, or if the Participant is not able to read, provide consent as stipulated by local laws and Human Research Ethics Committee (HREC) gu...